iRadimed (NASDAQ:IRMD) Sets New 12-Month High – Here’s What Happened

iRadimed Corporation (NASDAQ:IRMD) reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $101.00 and last traded at $100.3550, with a volume of 19622 shares. The stock had previously closed at $99.25.

Wall Street Analyst Weigh In

Several research firms have weighed in on IRMD. Wall Street Zen cut shares of iRadimed from a “strong-buy” rating to a “buy” rating in a report on Sunday, October 26th. Zacks Research upgraded iRadimed to a “hold” rating in a research note on Tuesday, November 4th. Weiss Ratings reissued a “buy (b-)” rating on shares of iRadimed in a report on Monday, December 29th. Roth Capital set a $90.00 price target on iRadimed in a research note on Friday, October 31st. Finally, Lake Street Capital reiterated a “buy” rating and set a $100.00 price objective on shares of iRadimed in a research report on Monday, November 3rd. Four research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $87.33.

iRadimed Trading Down 0.6%

The stock has a market cap of $1.30 billion, a P/E ratio of 61.82 and a beta of 1.09. The stock has a 50 day simple moving average of $94.41 and a 200 day simple moving average of $78.25.

iRadimed (NASDAQ:IRMD) last released its earnings results on Monday, November 3rd. The medical equipment provider reported $0.47 earnings per share for the quarter, beating analysts’ consensus estimates of $0.43 by $0.04. iRadimed had a return on equity of 22.93% and a net margin of 26.31%.The firm had revenue of $21.20 million during the quarter, compared to the consensus estimate of $20.50 million. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. Equities analysts anticipate that iRadimed Corporation will post 1.66 earnings per share for the current year.

iRadimed Dividend Announcement

The company also recently announced a special dividend, which was paid on Tuesday, December 30th. Stockholders of record on Wednesday, December 17th were given a $0.50 dividend. The ex-dividend date was Wednesday, December 17th. iRadimed’s payout ratio is presently 41.21%.

Insider Buying and Selling

In other iRadimed news, CFO John Glenn sold 15,000 shares of the company’s stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $97.29, for a total transaction of $1,459,350.00. Following the completion of the sale, the chief financial officer directly owned 7,362 shares in the company, valued at $716,248.98. This represents a 67.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Roger E. Susi sold 5,000 shares of the firm’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $97.45, for a total value of $487,250.00. Following the completion of the sale, the chief executive officer directly owned 2,272,500 shares in the company, valued at approximately $221,455,125. This represents a 0.22% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 60,000 shares of company stock valued at $5,451,200. 36.80% of the stock is currently owned by insiders.

Institutional Trading of iRadimed

Several institutional investors and hedge funds have recently modified their holdings of IRMD. CWM LLC boosted its stake in iRadimed by 62.2% in the third quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 211 shares in the last quarter. Quarry LP bought a new position in shares of iRadimed in the third quarter worth about $40,000. State of Alaska Department of Revenue acquired a new stake in shares of iRadimed in the 3rd quarter valued at approximately $47,000. Tower Research Capital LLC TRC grew its holdings in shares of iRadimed by 191.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock valued at $45,000 after purchasing an additional 495 shares during the last quarter. Finally, USA Financial Formulas acquired a new position in iRadimed during the 4th quarter worth approximately $82,000. 92.34% of the stock is currently owned by institutional investors.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.